Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Title:
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Author:
Brown, Jennifer R. Eichhorst, Barbara Hillmen, Peter Lamanna, Nicole O'Brien, Susan M. Tam, Constantine S. Qiu, Lugui Kaźmierczak, Maciej Jurczak, Wojciech Zhou, Keshu Šimkovič, Martin Mayer, Jiri Gillespie-Twardy, Amanda L. Ferrajoli, Alessandra Ganly, Peter S. Weinkove, Robert Grosicki, Sebastian Mital, Andrzej Robak, Tadeusz Österborg, Anders Yimer, Habte A. Salmi, Tommi Wang, Megan (Der Yu) Fu, Lina Li, Jessica Wu, Kenneth Cohen, Aileen Shadman, Mazyar